• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Strong Presence of Cellvizio at the OESO 14th World Conference, September 2017

Strong Presence of Cellvizio at the OESO 14th World Conference, September 2017

by Zina | Aug 31, 2017 | News

See the complete press release
Advancing data-driven surgery: Mauna Kea adds endomicroscope intelligence to robotic surgery toolkit

Advancing data-driven surgery: Mauna Kea adds endomicroscope intelligence to robotic surgery toolkit

by Zina | Aug 28, 2017 | Press Coverage

Mauna Kea adds endomicroscope intelligence to robotic surgery toolkit  By John Brosky, Contributing Writer, BioWorld MedTech PARIS – The Food and Drug Administration granted 510(k) clearance to Paris-based Mauna Kea Technologies SA to apply the...
Mauna Kea Technologies Receives Specific U.S. FDA 510(K) Clearance for use of Cellvizio during Robotic-Assisted Surgery

Mauna Kea Technologies Receives Specific U.S. FDA 510(K) Clearance for use of Cellvizio during Robotic-Assisted Surgery

by Zina | Aug 7, 2017 | News

Robotic-assisted surgery is one of the fastest growing surgical categories worldwide Key milestone in the Cellvizio product development roadmap, moving closer to data-driven surgery Mauna Kea Technologies today announced that it has received United States Food and...
Peer-Reviewed Publication of Key Multicenter Randomized Controlled Trial Demonstrating Improved Early Stomach Cancer Detection with Cellvizio

Peer-Reviewed Publication of Key Multicenter Randomized Controlled Trial Demonstrating Improved Early Stomach Cancer Detection with Cellvizio

by Zina | Aug 2, 2017 | News

Click to read complete Press Release
Mauna Kea Technologies Reports First Half 2017 Sales

Mauna Kea Technologies Reports First Half 2017 Sales

by Zina | Jul 25, 2017 | News

Click to read more
« Older Entries
Next Entries »

Articles récents

  • ‘Never a Dull Moment’ Dr. Ravi Prakash Keeps Patients Front and Center
  • Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 
  • Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 
  • Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 
  • Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}